DexCom, Inc.
Rank #114HypergrowthDXCM · Nasdaq · Healthcare
DexCom, Inc. (DXCM) — Rank #114 by gross profitability (GP/assets 0.43) · ROE 31.9% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001093557 · all metrics point-in-time as of the filing date.
About
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Show moreShow less
The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
The company was incorporated in 1999 and is headquartered in San Diego, California.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- dexcom.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2020-12-31filed 2021-02-11 | 2019-12-31filed 2020-02-13 | 2018-12-31filed 2019-02-21 | 2017-12-31filed 2018-02-27 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 67.1 | 48.7 | 29.1 | 16.1 |
| Stock-based compensation | 119.4 | 102.7 | 101.9 | 106.2 |
| Change in receivables | 142.3 | 60.0 | 93.2 | 31.8 |
| Change in inventory | 114.5 | 49.1 | 25.5 | (0.4) |
| Operating cash flow | 475.6 | 314.5 | 123.2 | 92.0 |
| Investing | ||||
| Capital expenditures | 199.0 | 180.0 | 67.1 | 66.0 |
| Acquisitions, net of cash | 0.0 | 0.0 | 11.3 | — |
| Investing cash flow | (1,018.0) | (1,015.2) | (139.8) | (144.4) |
| Financing | ||||
| Debt issued | — | — | — | — |
| Debt repaid | — | — | — | 0.0 |
| Share repurchases | 0.0 | 0.0 | 100.0 | — |
| Financing cash flow | 912.1 | 10.7 | 710.4 | 399.1 |
| Summary | ||||
| Free cash flow | 276.6 | 134.5 | 56.1 | 26.0 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?